Hemostatic Therapy for ICH - Updated Guidelines

• The AHA/ASA just published updated guidelines for the diagnosis and treatment of acute spontaneous intracerebral hemorrhage (ICH).
• Regarding hemostatic therapy, new/revised recommendations from the 2007 AHA/ASA guidelines include:
  • Patients with severe thrombocytopenia or factor deficiency should receive platelets or factor replacement
  • Patients with ICH due to oral anticoagulants (warfarin) should receive intravenous vitamin-K and vitamin-K dependent factor replacement
    • Prothrombin complex concentrates (PCCs) are being increasingly used and are considered a reasonable alternative to FFP.  To date, studies have not shown improved outcome with PCCs.
    • Recombinant factor VIIa (rFVIIa) is not recommended as a sole agent for warfarin-related ICH
  • rFVIIa is not recommended in unselected patients
  • Usefulness of platelet transfusions for patients using antiplatelet medications is unclear and currently investigational.

References

Morgenstern LB, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke 2010;41:00-00.